Condition: GIST · Sponsor: Deciphera Pharmaceuticals, LLC
This is a Phase 1/2, multicenter, open-label (unless otherwise specified in a combination-specific module) study of inlexisertib in combination with anticancer therapies. Modules within the master protocol are defined according to different combinations of inlexisertib with other anticancer agents.
This description comes directly from the study's public registry record.
Clinical Team · 888-724-3274 · Clinicaltrials@deciphera.com
Always discuss trial participation with your own doctor first.
| University of Southern California - Norris Comprehensive Cancer Center | Los Angeles, California, United States | Recruiting |
| UCLA Department of Medicine-Hematology/Oncology | Los Angeles, California, United States | Recruiting |
| Sylvester Comprehensive Cancer Center | Miami, Florida, United States | Recruiting |
| University of Massachusetts Worcester | Worcester, Massachusetts, United States | Recruiting |
| START Midwest | Grand Rapids, Michigan, United States | Recruiting |
| Washington University School of Medicine - Siteman Cancer Center | St Louis, Missouri, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center - Main Campus | New York, New York, United States | Recruiting |
| Cleveland Clinic Taussig Cancer Center | Cleveland, Ohio, United States | Recruiting |
| Oregon Health & Science University | Portland, Oregon, United States | Recruiting |
| Fox Chase Cancer Center | Philadelphia, Pennsylvania, United States | Recruiting |
| Virginia Cancer Specialist, PC | Fairfax, Virginia, United States | Recruiting |
| Aarhus University Hospital | Aarhus, Denmark | Recruiting |
+ 16 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05957367